Assessing the economic challenges posed by orphan drugs

Historically, patients with rare diseases have been underserved by commercial drug development. In several jurisdictions, specific legislation has been enacted to encourage the development of drugs for rare diseases (orphan drugs), which would otherwise not be commercially viable. However, because o...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of technology assessment in health care Ročník 23; číslo 1; s. 36 - 42
Hlavní autori:	Drummond, Michael F., Wilson, David A., Kanavos, Panos, Ubel, Peter, Rovira, Joan
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	New York, USA Cambridge University Press 01.01.2007
Predmet:	Cost analysis Cost-Benefit Analysis Cost-effectiveness analysis Disease Drugs Equity Europe FDA approval GENERAL ESSAYS Health care policy Health Policy Health services Health technology assessment Hospitals Humans Legislation Medical ethics Orphan Drug Production - economics Patients Pharmaceutical industry Rare diseases Reimbursement Support groups Technological change Technology Assessment, Biomedical United States United States Europe Equity Cost-effectiveness analysis Health policy
ISSN:	0266-4623, 1471-6348
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!